Crocs Cracks Before Christmas

Crocs shares crashed 11.63% to five-month lows today after the company bought Heydude, an Italian casual footwear company.

$CROX dropped as investors worry about how the shoe company will fund the $2.5 billion acquisition. Crocs will take out a $2 billion loan and a $50 million credit under an existing revolving facility with its bankers to cover the $2.05 billion cash portion of the deal. 😬 Crocs will also issue the Heydude founder and CEO, Alessandro Rosano, $450 million in $CROX shares.

The deal is anticipated to close in Q1 of 2022. Once the acquisition is completed, Heydude will function as a separate entity with Rosano continuing to head the firm.

Crocs CEO Andrew Rees stated: “With the acquisition of Heydude, we are thrilled to add another high-growth, highly profitable brand to our portfolio. We believe Heydude’s casual, comfortable, and lightweight products are aligned to long-term consumer trends and are a perfect fit for Crocs.”

$CROX is still up 97.6% YTD.

More in   Stocks

View All

Semi Stocks Continue To Soar

Semiconductor stocks remain the focus of investors and traders, with Nvidia and Super Micro Computer pushing to all-time highs. The industry is starting the week with several analyst upgrades as Wall Street continues to chase these companies higher. 🌠

Despite the growing concern that the fundamentals may not fully support these short-term surges in price, the path of least resistance remains higher.

Read It

Traders’ Updated S&P 500 Roadmap

Just because the calendar changes dates doesn’t mean the market’s trends do. As such, now seems like a great time to update the S&P 500 roadmap many traders used throughout 2023. πŸ—ΊοΈ

Below is a two-year daily candlestick chart with a few key indicators. The first is the 200-day moving average (blue), which traders use to track the long-term trend in the market. The next two are the anchored volume weighted average price (AVWAP) from the market’s 2022 highs and 2022 lows. Traders use this to track how the average buyer/seller has fared in the market from a specific date.

Read It

Biotech Investors Target PHAT Gains

As we’ve been highlighting for a long time, investors and traders continue to seek opportunities in the micro and small-cap healthcare space in hopes of a buyout.

With the most prominent players sitting on tons of cash and needing their next growth driver, it seems like there’s a new company being acquired every day. πŸ€‘

Read It

Stocktwits 2023 Year In Review

What a year it’s been for markets in 2023, with crypto soaring, tech stocks battling back, the economy staying upright, regional banks collapsing, and the Fed setting the stage to cut rates.Β 

The Stocktwits community was on top of it all, so what better way to recap the year than with some of our platform’s unique data? Let’s dive into it. πŸ‘‡

Read It